BRPI0409984A - process for changing insulin pharmacokinetics - Google Patents
process for changing insulin pharmacokineticsInfo
- Publication number
- BRPI0409984A BRPI0409984A BRPI0409984-2A BRPI0409984A BRPI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- processes
- present
- prevention
- treatment
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 12
- 102000004877 Insulin Human genes 0.000 title abstract 6
- 108090001061 Insulin Proteins 0.000 title abstract 6
- 229940125396 insulin Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 230000000291 postprandial effect Effects 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3286—Needle tip design, e.g. for improved penetration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
"PROCESSO PARA ALTERAR A FARMACOCINéTICA DA INSULINA". A presente invenção se refere a processos para a administração de insulina a um compartimento intradérmico da pelo de um indivíduo, de preferência à vascularização dérmica do compartimento intradérmico. Os processos da presente invenção aumentam os parâmetros farmacocinéticos e farmacodinâmicos da insulina distribuída e resultam eficazmente em uma eficácia clínica superior no tratamento e/ou prevenção de diabetes melito. Os processos da presente invenção proporcionam um melhor controle glicêmico tanto dos níveis de glicose sangüínea não em jejum (isto é, pós-prandiais), quanto em jejum e, portanto, têm uma maior eficácia terapêutica no tratamento, prevenção e/ou controle de diabetes, com relação a processos tradicionais de distribuição de insulina, incluindo a distribuição subcutânea de insulina."Process for changing insulin pharmacokinetics". The present invention relates to methods for administering insulin to an intradermal compartment of an individual's hair, preferably to dermal vascularization of the intradermal compartment. The processes of the present invention increase the pharmacokinetic and pharmacodynamic parameters of distributed insulin and effectively result in superior clinical efficacy in the treatment and / or prevention of diabetes mellitus. The processes of the present invention provide improved glycemic control of both fasting (i.e. postprandial) and fasting blood glucose levels and thus have greater therapeutic efficacy in the treatment, prevention and / or control of diabetes. , with respect to traditional insulin delivery processes, including subcutaneous insulin distribution.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/429,973 US7722595B2 (en) | 2002-05-06 | 2003-05-06 | Method and device for controlling drug pharmacokinetics |
| US50095603P | 2003-09-05 | 2003-09-05 | |
| US10/704,035 US20050010193A1 (en) | 2002-05-06 | 2003-11-06 | Novel methods for administration of drugs and devices useful thereof |
| US52383103P | 2003-11-19 | 2003-11-19 | |
| PCT/US2004/014033 WO2004101023A2 (en) | 2003-05-06 | 2004-05-06 | A method for altering insulin pharmacokinetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0409984A true BRPI0409984A (en) | 2006-05-09 |
Family
ID=33459121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409984-2A BRPI0409984A (en) | 2003-05-06 | 2004-05-06 | process for changing insulin pharmacokinetics |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1620145A4 (en) |
| JP (1) | JP2007517768A (en) |
| KR (1) | KR20060009303A (en) |
| AU (1) | AU2004238257A1 (en) |
| BR (1) | BRPI0409984A (en) |
| CA (1) | CA2524444A1 (en) |
| MX (1) | MXPA05011768A (en) |
| WO (1) | WO2004101023A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
| US10105317B2 (en) * | 2009-07-07 | 2018-10-23 | Anpac Bio-Medical Science Co., Ltd. | Method of drug delivery |
| EP3134110A1 (en) * | 2014-04-25 | 2017-03-01 | Sanofi | New administration routes of insulin, insulin analogs or derivatives of insulin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623457B1 (en) * | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
| US20020156453A1 (en) * | 1999-10-14 | 2002-10-24 | Pettis Ronald J. | Method and device for reducing therapeutic dosage |
| US6565532B1 (en) * | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
| US6607513B1 (en) * | 2000-06-08 | 2003-08-19 | Becton, Dickinson And Company | Device for withdrawing or administering a substance and method of manufacturing a device |
| CA2444377C (en) * | 2001-04-13 | 2014-09-02 | Paul G. Alchas | Method of intradermally injecting substances |
| BR0210628A (en) * | 2001-06-29 | 2004-08-10 | Becton Dickinson Co | Intradermal release of vaccines and genetic therapeutic agents via microcannula |
| US7556615B2 (en) * | 2001-09-12 | 2009-07-07 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
-
2004
- 2004-05-06 CA CA002524444A patent/CA2524444A1/en not_active Abandoned
- 2004-05-06 WO PCT/US2004/014033 patent/WO2004101023A2/en not_active Ceased
- 2004-05-06 BR BRPI0409984-2A patent/BRPI0409984A/en not_active Application Discontinuation
- 2004-05-06 EP EP04751427A patent/EP1620145A4/en not_active Withdrawn
- 2004-05-06 KR KR1020057021081A patent/KR20060009303A/en not_active Ceased
- 2004-05-06 AU AU2004238257A patent/AU2004238257A1/en not_active Abandoned
- 2004-05-06 MX MXPA05011768A patent/MXPA05011768A/en unknown
- 2004-05-06 JP JP2006532794A patent/JP2007517768A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2524444A1 (en) | 2004-11-25 |
| KR20060009303A (en) | 2006-01-31 |
| EP1620145A2 (en) | 2006-02-01 |
| MXPA05011768A (en) | 2006-01-26 |
| WO2004101023A2 (en) | 2004-11-25 |
| WO2004101023A3 (en) | 2007-03-01 |
| JP2007517768A (en) | 2007-07-05 |
| EP1620145A4 (en) | 2010-08-25 |
| AU2004238257A1 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bode et al. | Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes | |
| Raskin et al. | Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs | |
| Kann et al. | Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride | |
| Garg et al. | Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine | |
| Raskin et al. | Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. | |
| Hamann et al. | A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes | |
| McSorley et al. | Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus | |
| Bode | Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues—aspart, lispro, and glulisine | |
| Pitt et al. | Factors influencing insulin absorption around exercise in type 1 diabetes | |
| Black et al. | The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation | |
| NZ592283A (en) | Combination of an insulin and the GLP-1 agonist AVE0010 | |
| Maiorino et al. | Treatment satisfaction and glycemic control in young type 1 diabetic patients in transition from pediatric health care: CSII versus MDI | |
| Woo | A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus | |
| Davidson et al. | Biphasic insulin aspart 30: literature review of adverse events associated with treatment | |
| BRPI0409984A (en) | process for changing insulin pharmacokinetics | |
| Rave et al. | Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects | |
| Standl | Insulin analogues–State of the art | |
| Joshi et al. | Designer insulins regimens in clinical practice-pilot multicenter indian study | |
| Choe et al. | New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs | |
| Kapural et al. | Decreased insulin requirements with spinal cord stimulation in a patient with diabetes | |
| Cander et al. | The effect of basal analog insulin on the glycemic variability in type 2 diabetics. | |
| Triplitt | Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough? | |
| WO2012141764A3 (en) | Pre-operative use of metabolic activation therapy | |
| Annabestani et al. | Insulin buccal spray (Oral-Lyn) efficacy in type 1 diabetes | |
| Iafusco | Insulin therapy regimens in paediatric age |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal: dismissal of application maintained |